As of early 2009, NicOx has successfully completed its phase III clinical studies for naproxcinod (NO added to naproxen), a new class of Non-Steroidal Anti-Inflammatory Drug, targetting Osteoarthritis. The goals were to statistically demonstrate that : a) pain is reduced and motricity improved...